



Press Release

Goodwin Biotechnology Kicks off Phase III Compliant Expansion

Plantation, FL (January 30, 2006)

Goodwin Biotechnology, Inc. (GBI), one of the world's first established biological contract manufacturers, is staged for growth. Goodwin has recently begun an expansion project that will nearly double the GMP manufacturing space in its 23,000 square foot facility in Plantation, FL.

The new manufacturing suites will be initially outfitted with two STIR-TANK bioreactors, sized at 250 Liters and 750 Liters. Late summer of 2006 is the scheduled completion of the expansion project, including installation of the bioreactors. "Goodwin has a long history in the Biopharmaceutical arena. In the mid-eighties, our predecessor company was one of the first cancer research institutes to develop monoclonal antibody based diagnostics and therapeutics. Early in the 1990s, we became a fully integrated contract manufacturer of bio-therapeutics. This expansion project will enable us to serve our current and new clients as they scale up into Phase III trials and beyond," stated Ms. Stephanie Finnegan, Chief Executive Officer of Goodwin.

Having just completed an unprecedented year of growth in 2005, and with even more impending growth in sight, GBI is continuing to build its team and has added significant new staffing, especially in GMP manufacturing, quality, and regulatory affairs. Earlier in 2005, the GMP manufacturing space was upgraded and the QC labs enlarged. The expansion project will also encompass a new, larger, and more versatile process development laboratory, providing full services for both cell culture development and optimization as well as purification and conjugation process development. In early 2005, Goodwin negotiated a contract for and began manufacturing its first Phase III product, a recombinant biopharmaceutical for a global pharmaceutical company.

In reference to the expansion Mr. Karl Pinto, Chairman of Goodwin added, "We are looking to the future to establish ourselves as the leading bio processing services company. Our intentions are to continue partnering with biopharmaceutical companies looking for a contract manufacturer for pre-clinical through Phase III clinical trial production of recombinant proteins and monoclonal antibodies. We will also focus on building a franchise in the contract manufacturing of licensed "Orphan Drugs" and other large molecules for small to mid-sized patient markets."

About Goodwin Biotechnology, Inc

GBI is a contract manufacturing organization (CMO) specializing in the cGMP compliant mammalian cell culture of bio-therapeutics for pre-clinical through Phase III clinical trials. The company and its predecessor have been operating in the biologics CMO space since the early eighties. GBI's clients include small to mid-sized biotech companies, renowned cancer research institutes and various branches of the U.S. government.

For more information, please contact:

Goodwin Biotechnology Inc.
Stephanie Finnegan
(954) 327-9606